Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
Agomab Therapeutics NVAgomab Therapeutics NV(US:AGMB) Reuters·2026-02-06 17:48

Shares of Agomab Therapeutics fell about 8% in their Nasdaq debut on Friday, valuing the Belgium-based company at $716.4 million. ...